Tag

Falgun V. Savani

2 articles

PAR Drugs Q4 Net Profit Falls 83% YoY

PAR Drugs board approved audited FY26 results with standalone net profit of ₹1,310.86 lakh, down 27% YoY. Auditor issued unmodified opinion but highlighted SEBI order restraining proposed business tra

Par Drugs Board Approves FY26 Results Amid SEBI Restraint

Par Drugs board approved audited standalone financial results for Q4 and FY26 ended March 31, 2026, with an unmodified audit opinion. SEBI has restrained the company's proposed business transfer arran